Using the previously published prevalence rates for the Ultrio ID-NAT and HBsAg screened donations in four geographical regions for five infection stages, the prevalence rates for Ultrio Plus were predicted for three donation categories (first-time, lapsed plus repeat and all donations) as described in the methods and presented in Supplementary Tables S1 and S2. This evidence concerns the gene BRD2 and infection.